Search
pralsetinib (Gavreto)
Indications:
- adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
* detected by an FDA approved test
Contraindications:
- pregnancy
Dosage:
- 400 mg orally once daily on an empty stomach
* no food intake for at least 2 hours before * at least 1 hour after
Capsules: 100 mg
Adverse effects:
- >25%
- fatigue, constipation, musculoskeletal pain, hypertension
- laboratory abnormalities (>2%)
- lymphopenia, neutropenis, hypophosphatemisa, anemia, hyponatremia, hypocalcemia, increased serum ALT
- warnings
- interstitial lung disease
- hepatotoxicity
- hemorrhage
- hypertension
- impaired wound healing
Drug interactions:
- strong CYP3A inducers &/or inhibitors; void coadministration.
Mechanism of action:
- tyrosine kinase inhibitor of wild-type RET & oncogenic RET fusions
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
References
- Gavreto (pralsetinib) capsules, for oral use